Results 21 to 30 of about 20,028 (211)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia

Медицинский совет, 2021
Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different ...
A. A. Shikaleva, M. L. Maximov, N. M. Kiseleva   +2 more
doaj   +1 more source

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Atherosclerosis Plus, 2021
Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels.
Maria Giovanna Lupo, Diletta Arcidiacono, Alice Zaramella, Fabio Fimiani, Paolo Calabrò, Angelo Baldassare Cefalù, Maurizio Averna, Laura D'Erasmo, Marcello Arca, Sara De Martin, Alberto Zambon, Nicola Ferri   +11 more
doaj   +1 more source

Inhibitors of PCSK9

Revue medicale suisse, 2017
Observational data show a consistent association between elevated low density lipoproteins (LDL-C) and cardiovascular disease (CVD). Reduction of LDL-C reduces the risk of CVD as has been shown by many trials. Statins are currently the most effective drugs for lowering LDL-C, but can present side effects which might limit the prescribed dosage and ...
Petrova-Slater, Iveta, Denegri, Andrea, Pasotti, Elena, Rossi, Maria Grazia, Spirk, David, Riesen, Walter F, Moccetti, Tiziano, Moccetti, Marco   +7 more
openaire   +3 more sources

PCSK9 Inhibitors

Cell, 2016
Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative
Pradeep, Natarajan, Sekar, Kathiresan
openaire   +2 more sources

Polymorphic Variant rs11206510 in PCSK9 and Risk of Coronary Artery Disease in Bulgarians

Acta Medica Bulgarica, 2023
The aim of this study was to investigate the potential association of rs11206510 in PCSK9 gene with coronary artery disease (CAD) and myocardial infarction (MI) in Bulgarians.
Tzveova R., Yaneva-Sirakova T., Naydenova G., Vandeva S., Pendicheva-Duhlenska D., Atanasov P., Mitev V., Kaneva R.   +7 more
doaj   +1 more source

Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome

Renal Failure, 2020
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a major post-transcriptional regulator of low-density lipoprotein receptor degradation. Recently, PCSK9 was shown to be overexpressed by liver cells in rats with proteinuria.
Huaying Shen, Sheng Feng, Ying Lu, Linsen Jiang, Tingting Yang, Zhi Wang   +5 more
doaj   +1 more source

PCSK9 Association With Lipoprotein(a) [PDF]

Circulation Research, 2016
Rationale: Lipoprotein(a) [Lp(a)] is a highly atherogenic low-density lipoprotein–like particle characterized by the presence of apoprotein(a) [apo(a)] bound to apolipoprotein B. Proprotein convertase subtilisin/kexin type 9 (PCSK9) selectively binds low-density lipoprotein; we hypothesized that it ...
Hagai, Tavori, Devon, Christian, Jessica, Minnier, Deanna, Plubell, Michael D, Shapiro, Calvin, Yeang, Ilaria, Giunzioni, Mikael, Croyal, P Barton, Duell, Gilles, Lambert, Sotirios, Tsimikas, Sergio, Fazio   +11 more
openaire   +2 more sources

Safety of PCSK9 inhibitors

Biomedicine & Pharmacotherapy, 2022
annually in Europe, 4 million people die from cardiovascular diseases, the main cause of which is atherosclerosis. In order to slow down the development of atherosclerotic plaques, the main therapeutic goal is to lower LDL cholesterol (LDL-C) level. Undoubtedly, statins are the basis of lipid-lowering therapy for many years.
Grzegorz, Grześk, Bednarska, Dorota, Łukasz, Wołowiec, Anna, Wołowiec, Joanna, Osiak, Mariusz, Kozakiewicz, Joanna, Banach   +6 more
openaire   +2 more sources

PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration

American Journal of Medicine Open, 2023
Background: Real-world data on use of PCSK9 inhibitors (PCSK9-Is), with or without statins and/or ezetimibe, and associated outcomes, can inform more effective prescribing.
Jessica Eloso, Asma Awad, Xinhua Zhao, Francesca E. Cunningham, Rongping Zhang, Diane Dong, Cathy Kelley, Peter A. Glassman, Sherrie L. Aspinall   +8 more
doaj   +1 more source

Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-α: potential underlying mechanisms

Arthritis Research & Therapy, 2021
Background Proprotein convertase subtilisin kexin 9 (PCSK9) targets the LDL-receptor (LDLR) which raises LDL-levels. In addition, PCSK9 has proinflammatory immunological effects.
Johan Frostegård, Sabbir Ahmed, Ingiäld Hafström, Sofia Ajeganova, Mizanur Rahman   +4 more
doaj   +1 more source